COO’s 1,875 PSU Purchase Signals Confidence Amid Sarepta’s Share‑Price Slide

Insider Buying Signals in a Volatile Biotech Landscape

Sarepta Therapeutics Inc. (NASDAQ: SRPT) reported a notable insider transaction on February 25 2026 when its Chief Operating Officer, Ian Michael Estepan, acquired 1,875 performance‑stock units (PSUs). At the prevailing market price of $16.76 per share, the purchase represented an outlay of approximately $31,500. While modest in absolute terms relative to the company’s market capitalization, the move signals executive confidence during a period marked by earnings uncertainty and leadership turnover.

Transaction Mechanics and Vesting Conditions

The PSUs acquired by Estepan will vest on March 1 2026, subject to continued employment and the achievement of designated performance milestones. This structure aligns the officer’s financial upside with Sarepta’s clinical and commercial trajectory, thereby linking insider activity to the company’s long‑term value creation.

Market Context and Investor Interpretation

Sarepta’s shares have experienced a 26 % month‑over‑month decline and an 84 % year‑to‑date slide. Insider purchases amid such volatility can serve as a counter‑balance to market pessimism, suggesting that senior management views the recent revenue shortfall as a temporary setback rather than a systemic issue. Investors may interpret the COO’s buy as an endorsement of the exon‑skipping pipeline and an expectation of future therapeutic breakthroughs.

Historical Insider Trading Patterns

Estepan’s trading history illustrates a strategic approach to portfolio management. In December 2025, he sold 13,187 shares at $22.31 each, reducing his stake from roughly 193 k to 156 k shares. Earlier that year, he executed two significant purchases—93,875 and 50,000 shares—increasing his holdings to 206 k shares. The recent acquisition of 1,875 PSUs aligns with this pattern of rebalancing: substantial sales when the price is elevated, followed by disciplined buying as the market dips. This strategy preserves liquidity while securing upside potential.

Broader Insider Activity

The same day, President Louise Rodino‑Klapac added 1,875 PSUs, and the retirement announcement of senior executive Doug Ingram has already begun to shift investor sentiment. The collective buying by top executives may act as a stabilizing force, reinforcing the notion that the leadership team remains committed to the company’s strategic vision despite recent volatility.

Implications for Future Development and Financing

Should the PSUs vest and Sarepta meet its performance milestones, the resulting liquidity could be deployed to:

1. Accelerate late‑stage clinical trials, notably the Phase 3 EMBARK study for exon‑skipping therapy in Duchenne muscular dystrophy.
2. Strengthen the balance sheet in anticipation of regulatory scrutiny and potential market fluctuations.
3. Align executive incentives more closely with long‑term shareholder value, potentially reducing agency costs.

The central question for investors will be whether executive optimism translates into tangible clinical milestones and whether the company can restore market confidence that has been eroded by the recent share price decline.

Insider Transaction Table (Summary)

Note: The price per share is listed as 0.00 because PSUs are typically awarded without a cash payment; their value is realized upon vesting.